Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacityWARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet

Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacityWARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14.
 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2950758/Dr_Jonathan_M_Vigdorchik___Zimmer_Biomet.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2950758/Dr_Jonathan_M_Vigdorchik___Zimmer_Biomet.jpg" title="Dr. Jonathan M. Vigdorchik, Chief Science, Technology and Medical Affairs Officer, Zimmer Biomet" alt="Dr. Jonathan M. Vigdorchik, Chief Science, Technology and Medical Affairs Officer, Zimmer Biomet"></img>
 </a>
 
 </div>
In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company&#39;s global end-to-end technology portfolio, including AI, robotics, smart implants and data. He will also oversee Zimmer Biomet&#39;s Medical Education strategy and Global Advisory Board, helping further strengthen Zimmer Biomet&#39;s clinical engagement, innovation roadmap and external scientific leadership. Dr. Vigdorchik will report to Ivan Tornos, Chairman, President and Chief Executive Officer.&#34;Dr. Vigdorchik is a world-class orthopedic surgeon, and he brings exactly the kind of bold, future-focused leadership we need as we continue to shape the next era of musculoskeletal care,&#34; said Tornos. &#34;He understands how to translate clinical insight into meaningful innovation, and his leadership will help us move faster, think bigger and continue advancing our broad suite of robotic and enabling technologies. I&#39;m confident he will play a critical role in accelerating our portfolio strategy and further differentiating Zimmer Biomet in the market.&#34;Dr. Vigdorchik previously served as Zimmer Biomet&#39;s Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants. He is a board-certified, fellowship-trained orthopedic surgeon at Hospital for Special Surgery (HSS) in New York City, specializing in hip and knee replacement surgery. Dr. Vigdorchik held several prominent academic and clinical leadership positions, including serving as Division Chief for national/international reputation and academic promotion on the Adult Reconstruction and Joint Replacement service at HSS and Director of Bone Implant Longevity Research at HSS&#39;s Griffin Research Accelerator. In addition, he is currently an Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College. He is active in professional societies including The Hip Society, The Knee Society, the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS), where he served as the Education and Communications Council Chair and earlier served as Program Chair for the 2024 AAHKS Annual Meeting.&#34;As a surgeon and innovator, I believe we are at an inflection point where AI, data, and advanced technology will fundamentally redefine the future of orthopedics,&#34; said Dr. Vigdorchik. &#34;I&#39;ve dedicated my career to focus on preventing complications and achieving consistently better outcomes for patients. With strength across its product portfolio, a differentiated suite of robotic and enabling technologies, and a pathway toward fully autonomous robotic technology in orthopedics, Zimmer Biomet is poised to continue pushing the industry forward. I&#39;m excited to join the talented team in this expanded role to help advance that vision and accelerate innovation for surgeons and patients around the world.&#34;Dr. Vigdorchik earned his medical degree from the University of Missouri – Columbia School of Medicine, completed his orthopaedic surgery residency at the Detroit Medical Center / Providence Hospital, and received fellowship training in Adult Reconstruction and Joint Replacement at HSS. He also completed an international traveling fellowship in hip preservation surgery with training at centers in Switzerland, Boston Children&#39;s Hospital, and Washington University in St. Louis.About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4658061-1&amp;h=3468072615&amp;u=http%3A%2F%2Fwww.zimmerbiomet.com%2F&amp;a=www.zimmerbiomet.com" target="_blank" rel="nofollow">www.zimmerbiomet.com</a> or follow on LinkedIn at <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4658061-1&amp;h=2806517861&amp;u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fzimmerbiomet&amp;a=www.linkedin.com%2Fcompany%2Fzimmerbiomet" target="_blank" rel="nofollow">www.linkedin.com/company/zimmerbiomet</a> or X at <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4658061-1&amp;h=1225470740&amp;u=http%3A%2F%2Fwww.x.com%2Fzimmerbiomet&amp;a=www.x.com%2Fzimmerbiomet" target="_blank" rel="nofollow">www.x.com/zimmerbiomet</a>.Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet&#39;s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet&#39;s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet&#39;s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.<div xmlns="http://www.w3.org/1999/xhtml"><table xmlns="http://www.w3.org/1999/xhtml" border="0" cellspacing="0" cellpadding="1" class="prnbcc"><tr xmlns="http://www.w3.org/1999/xhtml"><td xmlns="http://www.w3.org/1999/xhtml" class="prngen2" colspan="1" rowspan="1">Contacts: MediaTroy Kirkpatrick614-284-1926<a xmlns="http://www.w3.org/1999/xhtml" href="mailto:troy.kirkpatrick@zimmerbiomet.com" target="_blank" class="prnews_a" rel="nofollow">troy.kirkpatrick@zimmerbiomet.com</a>  Kirsten Fallon781-779-5561<a xmlns="http://www.w3.org/1999/xhtml" href="mailto:kirsten.fallon@zimmerbiomet.com" target="_blank" class="prnews_a" rel="nofollow">kirsten.fallon@zimmerbiomet.com</a> </td><td xmlns="http://www.w3.org/1999/xhtml" class="prngen2" colspan="1" rowspan="1">  InvestorsDavid DeMartino646-531-6115<a xmlns="http://www.w3.org/1999/xhtml" href="mailto:david.demartino@zimmerbiomet.com" target="_blank" class="prnews_a" rel="nofollow">david.demartino@zimmerbiomet.com</a>  Zach Weiner908-591-6955<a xmlns="http://www.w3.org/1999/xhtml" href="mailto:zach.weiner@zimmerbiomet.com" target="_blank" class="prnews_a" rel="nofollow">zach.weiner@zimmerbiomet.com</a> </td></tr></table></div>
<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1603977/Zimmer_Biomet_Holdings_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1603977/Zimmer_Biomet_Holdings_Logo.jpg" title="(PRNewsfoto/Zimmer Biomet Holdings, Inc.)" alt="(PRNewsfoto/Zimmer Biomet Holdings, Inc.)"></img>
 </a>
 
</div>



<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=DE27873&amp;sd=2026-04-07"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/zimmer-biomet-appoints-dr-jonathan-m-vigdorchik-as-chief-science-technology-and-medical-affairs-officer-302735027.html" target="_blank">https://www.prnewswire.com/news-releases/zimmer-biomet-appoints-dr-jonathan-m-vigdorchik-as-chief-science-technology-and-medical-affairs-officer-302735027.html</a>SOURCE Zimmer Biomet Holdings, Inc.

Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

Zimmer Biomet appoints new Chief Science and Medical Affairs Officer

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacityWARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Zimmer Biomet has appointed Dr. Jonathan Vigdorchik as Chief Science, Technology, and Medical Affairs Officer, starting April 14, 2026. His extensive experience in orthopedic surgery and focus on advanced technologies such as AI and robotics are expected to bolster the company&#039;s innovation and market differentiation, potentially leading to improved growth prospects.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Jonathan Vigdorchik appointed as Chief Science and Medical Affairs Officer effective April 14.</li><li>He will oversee Zimmer Biomet&#039;s global technology strategies including AI and robotics.</li><li>Dr. Vigdorchik is a well-respected orthopedic surgeon with significant industry experience.</li><li>His leadership aims to enhance clinical engagement and innovation at Zimmer Biomet.</li><li>This change is expected to accelerate the company&#039;s technology and innovation strategies.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Zimmer Biomet (ZBH): Innovative leadership aims to enhance growth through advanced technology.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This news fits into &#039;Corporate Developments&#039; as it highlights executive leadership changes that may influence the company&#039;s strategic direction and innovation capacity, critical for maintaining competitive advantage in the medical technology sector.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Appointment of Dr. Vigdorchik signifies a strategic shift towards advanced technology.</li><li>Increased focus on AI and robotics could lead to innovative product offerings.</li><li>Strengthened clinical engagement may improve market positioning and sales.</li><li>Potential acceleration in product launch timelines could boost investor sentiment.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Dr. Vigdorchik starts on April 14, 2026.</li><li>He previously served as Chief Medical Technology Advisor at Zimmer Biomet.</li><li>Dr. Vigdorchik specializes in hip and knee replacement surgery.</li><li>He is associated with prestigious organizations like the American Academy of Orthopaedic Surgeons.</li><li>Zimmer Biomet has over 90 years of medical technology leadership.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Consider buying ZBH shares short-term as leadership changes may enhance growth potential.
 </section>
</section>


Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacityWARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14.
 <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2950758/Dr_Jonathan_M_Vigdorchik___Zimmer_Biomet.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2950758/Dr_Jonathan_M_Vigdorchik___Zimmer_Biomet.jpg" title="Dr. Jonathan M. Vigdorchik, Chief Science, Technology and Medical Affairs Officer, Zimmer Biomet" alt="Dr. Jonathan M. Vigdorchik, Chief Science, Technology and Medical Affairs Officer, Zimmer Biomet"></img>
 </a>
 
 </div>
In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company&#39;s global end-to-end technology portfolio, including AI, robotics, smart implants and data. He will also oversee Zimmer Biomet&#39;s Medical Education strategy and Global Advisory Board, helping further strengthen Zimmer Biomet&#39;s clinical engagement, innovation roadmap and external scientific leadership. Dr. Vigdorchik will report to Ivan Tornos, Chairman, President and Chief Executive Officer.&#34;Dr. Vigdorchik is a world-class orthopedic surgeon, and he brings exactly the kind of bold, future-focused leadership we need as we continue to shape the next era of musculoskeletal care,&#34; said Tornos. &#34;He understands how to translate clinical insight into meaningful innovation, and his leadership will help us move faster, think bigger and continue advancing our broad suite of robotic and enabling technologies. I&#39;m confident he will play a critical role in accelerating our portfolio strategy and further differentiating Zimmer Biomet in the market.&#34;Dr. Vigdorchik previously served as Zimmer Biomet&#39;s Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants. He is a board-certified, fellowship-trained orthopedic surgeon at Hospital for Special Surgery (HSS) in New York City, specializing in hip and knee replacement surgery. Dr. Vigdorchik held several prominent academic and clinical leadership positions, including serving as Division Chief for national/international reputation and academic promotion on the Adult Reconstruction and Joint Replacement service at HSS and Director of Bone Implant Longevity Research at HSS&#39;s Griffin Research Accelerator. In addition, he is currently an Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College. He is active in professional societies including The Hip Society, The Knee Society, the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS), where he served as the Education and Communications Council Chair and earlier served as Program Chair for the 2024 AAHKS Annual Meeting.&#34;As a surgeon and innovator, I believe we are at an inflection point where AI, data, and advanced technology will fundamentally redefine the future of orthopedics,&#34; said Dr. Vigdorchik. &#34;I&#39;ve dedicated my career to focus on preventing complications and achieving consistently better outcomes for patients. With strength across its product portfolio, a differentiated suite of robotic and enabling technologies, and a pathway toward fully autonomous robotic technology in orthopedics, Zimmer Biomet is poised to continue pushing the industry forward. I&#39;m excited to join the talented team in this expanded role to help advance that vision and accelerate innovation for surgeons and patients around the world.&#34;Dr. Vigdorchik earned his medical degree from the University of Missouri – Columbia School of Medicine, completed his orthopaedic surgery residency at the Detroit Medical Center / Providence Hospital, and received fellowship training in Adult Reconstruction and Joint Replacement at HSS. He also completed an international traveling fellowship in hip preservation surgery with training at centers in Switzerland, Boston Children&#39;s Hospital, and Washington University in St. Louis.About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4658061-1&amp;h=3468072615&amp;u=http%3A%2F%2Fwww.zimmerbiomet.com%2F&amp;a=www.zimmerbiomet.com" target="_blank" rel="nofollow">www.zimmerbiomet.com</a> or follow on LinkedIn at <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4658061-1&amp;h=2806517861&amp;u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fzimmerbiomet&amp;a=www.linkedin.com%2Fcompany%2Fzimmerbiomet" target="_blank" rel="nofollow">www.linkedin.com/company/zimmerbiomet</a> or X at <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4658061-1&amp;h=1225470740&amp;u=http%3A%2F%2Fwww.x.com%2Fzimmerbiomet&amp;a=www.x.com%2Fzimmerbiomet" target="_blank" rel="nofollow">www.x.com/zimmerbiomet</a>.Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet&#39;s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet&#39;s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet&#39;s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.<div xmlns="http://www.w3.org/1999/xhtml"><table xmlns="http://www.w3.org/1999/xhtml" border="0" cellspacing="0" cellpadding="1" class="prnbcc"><tr xmlns="http://www.w3.org/1999/xhtml"><td xmlns="http://www.w3.org/1999/xhtml" class="prngen2" colspan="1" rowspan="1">Contacts: MediaTroy Kirkpatrick614-284-1926<a xmlns="http://www.w3.org/1999/xhtml" href="mailto:troy.kirkpatrick@zimmerbiomet.com" target="_blank" class="prnews_a" rel="nofollow">troy.kirkpatrick@zimmerbiomet.com</a>  Kirsten Fallon781-779-5561<a xmlns="http://www.w3.org/1999/xhtml" href="mailto:kirsten.fallon@zimmerbiomet.com" target="_blank" class="prnews_a" rel="nofollow">kirsten.fallon@zimmerbiomet.com</a> </td><td xmlns="http://www.w3.org/1999/xhtml" class="prngen2" colspan="1" rowspan="1">  InvestorsDavid DeMartino646-531-6115<a xmlns="http://www.w3.org/1999/xhtml" href="mailto:david.demartino@zimmerbiomet.com" target="_blank" class="prnews_a" rel="nofollow">david.demartino@zimmerbiomet.com</a>  Zach Weiner908-591-6955<a xmlns="http://www.w3.org/1999/xhtml" href="mailto:zach.weiner@zimmerbiomet.com" target="_blank" class="prnews_a" rel="nofollow">zach.weiner@zimmerbiomet.com</a> </td></tr></table></div>
<div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2">
 
 <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1603977/Zimmer_Biomet_Holdings_Logo.html" target="_blank" rel="nofollow">
 <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/1603977/Zimmer_Biomet_Holdings_Logo.jpg" title="(PRNewsfoto/Zimmer Biomet Holdings, Inc.)" alt="(PRNewsfoto/Zimmer Biomet Holdings, Inc.)"></img>
 </a>
 
</div>



<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=DE27873&amp;sd=2026-04-07"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/zimmer-biomet-appoints-dr-jonathan-m-vigdorchik-as-chief-science-technology-and-medical-affairs-officer-302735027.html" target="_blank">https://www.prnewswire.com/news-releases/zimmer-biomet-appoints-dr-jonathan-m-vigdorchik-as-chief-science-technology-and-medical-affairs-officer-302735027.html</a>SOURCE Zimmer Biomet Holdings, Inc.

Zimmer Biomet has appointed Dr. Jonathan Vigdorchik as Chief Science, Technology, and Medical Affairs Officer, starting April 14, 2026. His extensive experience in orthopedic surgery and focus on advanced technologies such as AI and robotics are expected to bolster the company's innovation and market differentiation, potentially leading to improved growth prospects.

Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News